- Home
- RMAX vs GOSS Comparison
RMAX vs GOSS Comparison
Compare RMAX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | GOSS |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 104.7M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMAX | GOSS |
|---|---|---|
| Price | $6.78 | $0.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $9.00 | $4.19 |
| AVG Volume (30 Days) | 233.7K | ★ 9.7M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $195,929,000.00 | $48,471,000.00 |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.24 | $201.64 |
| P/E Ratio | $11.38 | ★ N/A |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $5.46 | $0.32 |
| 52 Week High | $10.32 | $3.87 |
Technical Indicators
Market Signals| Indicator | RMAX | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 70.46 | 37.32 |
| Support Level | $6.23 | $0.33 |
| Resistance Level | $7.91 | $0.60 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 92.16 | 52.61 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).